(NewsDirect)
BioVaxys CEO James Passin joins NatalieStoberman from the 35th International Papillomavirus Conference inWashington, D.C. to discuss its latest news of retaining New YorkCity-based Maxim Group as its financial advisor and investment banker.
Passin says Maxim will handlestrategic planning, assessment of potential strategic alliances andcapital requirements, and advising the company with respect to theprocess of obtaining a listing on a US national stock exchange.
BioVaxys is a clinical stage biotechnology company that isdeveloping viral and oncology vaccine platforms, as well asimmuno-diagnostics. The company is advancing vaccines for SARS-CoV-2,SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenizedviral protein technology, and is planning a clinical trial of itshaptenized autologous cell vaccine used in combination with anti-PD1and anti-PDL1 checkpoint inhibitors that will initially be developedfor Stage III/Stage IV ovarian cancer.
ContactDetails
Proactive Canada
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.